This one sounds a dream come true... 8)
Mr. Rick Pauls, CEO of DiaMedica: "A monoclonal antibody with potent dual capabilities to normalize blood glucose and blood pressure could replace currently used combination therapies of diabetic and anti-hypertensive drugs. These could be administered as infrequently as once a month. DM-204 has the potential to fundamentally change the treatment regimen for diabetic patients".
http://www.medilexicon.com/medicalnews.php?newsid=222967
Mr. Rick Pauls, CEO of DiaMedica: "A monoclonal antibody with potent dual capabilities to normalize blood glucose and blood pressure could replace currently used combination therapies of diabetic and anti-hypertensive drugs. These could be administered as infrequently as once a month. DM-204 has the potential to fundamentally change the treatment regimen for diabetic patients".
http://www.medilexicon.com/medicalnews.php?newsid=222967
